HIV-1-Induced Nuclear Pore Remodeling Licenses Infection of Resting T Cells

Study Background and Research Question

HIV-1 infection of CD4+ T cells is central to viral persistence and immune system compromise in AIDS. Notably, while resting T cells are abundant in lymphoid tissues and often harbor integrated provirus in vivo, they are highly resistant to infection by cell-free HIV-1 in vitro. This paradox has been attributed to the need for mitogenic activation, which renders T cells permissive to infection. However, whether infection of resting T cells in vivo results from direct infection or from previously activated cells returning to quiescence has remained unresolved. The reference study (Mesner et al., 2026) directly investigates the molecular barriers to HIV-1 infection in resting versus activated T cells and asks how HIV-1 overcomes these restrictions in physiological settings.

Key Innovation from the Reference Study

Mesner et al. reveal a previously unappreciated mechanism by which HIV-1 exploits cellular signalling during cell–cell spread (CCS) to remodel the nuclear pore complex (NPC) of resting T cells, thereby licensing infection. Specifically, HIV-1 engagement of CD4 at virological synapses (VS) triggers LCK–CDK1 signalling, leading to phosphorylation of nucleoporins and priming the NPC for efficient capsid nuclear import. This process bypasses the need for full T cell activation and explains why resting T cells can be directly infected in vivo through CCS—a route that dominates HIV-1 dissemination in lymphoid tissues.

Methods and Experimental Design Insights

The research team employed a combination of viral and cellular assays, super-resolution microscopy, and targeted mutagenesis to dissect the infection process. To decouple the effects of Env-dependent cell–cell contact from viral load, they engineered an HIV-1 mutant (Env-F522Y) incapable of membrane fusion. This allowed the authors to separate the signalling consequences of virological synapse formation from simple viral transfer. Quantitative analysis of nuclear import was performed by tracking fluorescently labelled HIV-1 capsid cores and monitoring their passage through the NPC into the nucleus of primary human T cells. The use of kinase activity assays and targeted inhibitors helped delineate the role of CD4–LCK–CDK1 signalling in NPC remodelling.

Core Findings and Why They Matter

The central finding is that nuclear import of HIV-1 capsid is a key rate-limiting step in the infection of resting T cells. Cell-free HIV-1 fails to trigger sufficient signalling for NPC remodeling, resulting in inefficient infection. In contrast, during CCS, engagement of CD4 by Env at the virological synapse activates LCK and, in turn, CDK1 independently of cell cycle progression. Activated CDK1 phosphorylates nucleoporins, altering NPC properties to facilitate capsid import. Notably, this mechanism operates in both resting and activated T cells, but is especially critical for overcoming the nuclear import bottleneck in resting cells. This accounts for the dominance of CCS in natural HIV-1 dissemination and provides a molecular explanation for the presence of infected resting T cells in vivo (Mesner et al., 2026).

These insights reshape our understanding of HIV-1 persistence: rather than being a passive consequence of T cell activation, resting CD4+ T cell infection is an actively regulated process driven by virus-induced signalling during cell–cell interactions. Therapeutic strategies that disrupt these signalling pathways or block NPC remodeling may present new avenues for limiting HIV-1 reservoir establishment.

Comparison with Existing Internal Articles

While the reference study focuses on HIV-1 nuclear import and T cell infection, parallels can be drawn with research on kinase signalling in other contexts. For example, "IPA-3: Precision Pak1 Inhibition for Advanced Signaling Studies" and "IPA-3: Strategic Pak1 Inhibition for Translational Research" discuss the use of selective Pak1 inhibitors such as 1-[(2-hydroxynaphthalen-1-yl)disulfanyl]naphthalen-2-ol (IPA-3) in dissecting kinase-regulated pathways relevant to cancer biology research, neuroinflammation, and cell motility. Although Pak1 is not the focus in the HIV-1 study, the experimental logic—using selective small-molecule inhibitors to delineate kinase cascades—shows strong methodological overlap. Both fields leverage kinase activity assays and pathway-specific inhibitors to probe regulatory checkpoints, whether in viral infection or oncology.

Insights from inhibitor-based virology studies, such as Wang et al. (2018) on reovirus entry, further illustrate the value of chemical tools for pinpointing stage-specific viral and host processes. While the kinases targeted differ, the experimental paradigm—using selective inhibition to clarify mechanistic steps—is a bridge across domains.

Limitations and Transferability

Despite its innovative approach, the study has several limitations. The findings are derived from in vitro and ex vivo assays, which, while sophisticated, may not fully capture the complexity of in vivo tissue environments. The exact spectrum of nucleoporins modified and the downstream effects of their phosphorylation require further mapping. Additionally, the study does not address whether similar mechanisms operate in other immune cell types or in the context of diverse HIV-1 strains. Finally, translating these mechanistic insights into therapeutic strategies will require careful evaluation of off-target effects and the feasibility of targeting host cell signalling without compromising immune function.

Protocol Parameters

• Virological synapse formation: Use mutant Env (e.g., Env-F522Y) to dissect contact-induced signalling from viral fusion events.
• Kinase activity assay: Measure CDK1 activation and nucleoporin phosphorylation following VS formation in resting and activated T cells.
• Super-resolution imaging: Quantify HIV-1 capsid nuclear import by tracking fluorescently tagged cores post cell–cell contact.
• Inhibitor studies: Employ selective kinase inhibitors to parse contributions of LCK and CDK1 to NPC remodeling; workflow suggestions from related kinase pathway studies recommend concentrations and timing based on cellular toxicity and target engagement.

Research Support Resources

To facilitate similar kinase pathway studies, researchers may utilize IPA-3 (SKU B2169), a selective, non-ATP-competitive Pak1 inhibitor that has proven utility in kinase activity assays and cell-based signalling analyses. IPA-3’s specificity for the autoregulatory domain enables precise mechanistic dissection of Pak1-regulated processes, as described in APExBIO’s protocol recommendations. While not directly applied in the HIV-1 study, such selective inhibitors are important resources for clarifying kinase-dependent mechanisms in virology and immune signalling. For further experimental guidance, consult related articles on workflow-driven Pak1 inhibition and advanced kinase assay optimization.